^
Association details:
| Biomarker: | ALK-HIP1 fusion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
P84.04 - HIP1-ALK Positive Non-Small-Cell Lung Cancer: Clinicopathological Characteristics and Prognosis
Published date:
01/12/2021
Excerpt:
...to describe the efficacy and safety of ALK inhibitors in HIP1-ALK positive NSCLC…8 cases received crizotinib or alectinib and all responded. 2 patients (25%) had a complete remission to crizotinib or alectinib with progression-free survival (PFS) beyond 9 months. Furthermore, 3 patients (37.5%) got a partial response to crizotinib or alectinib.
